Novonesis stock steadies after latest half year update

Published on 09/08/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novonesis stock is trading around the middle of its 52 week range after the latest half year 2026 update. Revenue, operating profit and guidance all point to a resilient first half.

Industrieanlage mit Fermentationstanks eines daenischen Biotech-Unternehmens — Fotorealistische Ansicht einer Biotech-Anlage von Novonesis (Novozymes), ISIN DK0060336014, mit modernen Fermentationstanks in Bagsvaerd, Illustration mit AI erstellt.

Novonesis stock (ISIN DK0060336014) traded around the middle of its 52 week range after the latest half year 2026 update, which ad-hoc-news said was still reflected in the shares as of September 4, 2026.

Half year figures stay firm

The half year 2026 report cited revenue in the first half of 2026 in the mid-single-digit billions of Danish kroner, with operating profit higher than in the first half of 2025 and a margin in the high-teens percent range. The same disclosure kept full year 2026 guidance unchanged, targeting revenue growth in the mid-single to low-double-digit percent range and an operating margin roughly stable versus the prior year.

For investors, the comparison matters more than the absolute level: revenue, operating profit and margin all improved against the first half of 2025, and the guidance was held rather than cut.

Range and valuation

The stock was described as sitting between the documented 52 week low and high on the Nasdaq Copenhagen listing as of September 4, 2026, with market value in the tens of billions of Danish kroner on that closing level. That keeps the chart from looking stretched, even after the latest earnings update.

Enzymes and ingredients

Novonesis, the Danish biosolutions group formed from Novozymes and Chr. Hansen, is anchored in enzymes, cultures and other biological ingredients used across food, household and industrial applications. That portfolio is what supports the revenue base behind the half year numbers.

Close of trade

The primary listing is Nasdaq Copenhagen and the reference currency is Danish kroner. The stock was last described at a mid range level on September 4, 2026, with the full year 2026 outlook still intact.